Literature DB >> 20853055

Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer.

Chee-Chee H Stucky1, Richard J Gray, Nabil Wasif, Amylou C Dueck, Barbara A Pockaj.   

Abstract

OBJECTIVES: Surgical therapy for invasive breast cancer includes breast conservation therapy (BCT), unilateral mastectomy (UM), or bilateral mastectomy, including contralateral prophylactic mastectomy (CPM) with or without reconstruction (± R). The goal of this study was to determine factors associated with CPM.
METHODS: A breast cancer database collected from 2000 through 2008 was retrospectively reviewed. Treatment groups analyzed included BCT, UM ± R, and CPM ± R. Variables were compared using ANOVA F-tests and chi-square tests. Multivariate analysis was performed using logistic regression.
RESULTS: A total of 1,391 patients underwent surgery for invasive breast cancer: 69% BCT, 21% UM, and 10% bilateral mastectomy. Of those undergoing bilateral mastectomy, 30% had bilateral cancer and were excluded from analysis. The rate of CPM increased significantly from 0 to 20% (p < 0.001), whereas the rate of UM remained relatively stable. Factors associated with CPM included younger age, significant family history, genetic testing, positive BRCA gene mutation, and preoperative magnetic resonance imaging (MRI). Tumor characteristics associated with CPM included positive axillary lymph node metastases and triple-negative disease (ER-/PR-/HER2 normal). Breast reconstruction was more common among women who underwent CPM (p < 0.001). On multivariate regression comparing BCT with CPM, younger age, larger tumors, multifocal disease, and MRI significantly predicted CPM. Comparing UM with CPM, only age and genetic testing significantly predicted CPM.
CONCLUSIONS: The rate of bilateral mastectomy for unilateral breast cancer is increasing. This is particularly true for younger patients with strong family history. The availability of breast reconstruction may play a role and the effects of stage and multifocal disease needs further exploration.

Entities:  

Mesh:

Year:  2010        PMID: 20853055     DOI: 10.1245/s10434-010-1259-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  23 in total

1.  Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.

Authors:  Shoshana M Rosenberg; Karen Sepucha; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Meghan E Meyer; Lidia Schapira; Steven E Come; Virginia F Borges; Mehra Golshan; Eric P Winer; Ann H Partridge
Journal:  Ann Surg Oncol       Date:  2015-05-01       Impact factor: 5.344

2.  Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers.

Authors:  Sunil Amin; Russell B McBride; Jennie K Kline; Elana B Mitchel; Aimee L Lucas; Alfred I Neugut; Harold Frucht
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 3.  Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer.

Authors:  Abenaa M Brewster; Patricia A Parker
Journal:  Oncologist       Date:  2011-06-14

4.  Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.

Authors:  Nrupen A Bhavsar; Lawrence J Appel; John W Kusek; Gabriel Contreras; George Bakris; Josef Coresh; Brad C Astor
Journal:  Am J Kidney Dis       Date:  2011-09-22       Impact factor: 8.860

5.  Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study.

Authors:  Andrea L Pusic; Evan Matros; Neil Fine; Edward Buchel; Gayle M Gordillo; Jennifer B Hamill; Hyungjin M Kim; Ji Qi; Claudia Albornoz; Anne F Klassen; Edwin G Wilkins
Journal:  J Clin Oncol       Date:  2017-03-27       Impact factor: 44.544

6.  B-Sure: a randomized pilot trial of an interactive web-based decision support aid versus usual care in average-risk breast cancer patients considering contralateral prophylactic mastectomy.

Authors:  Sharon L Manne; Barbara L Smith; Sara Frederick; Anna Mitarotondo; Deborah A Kashy; Laurie J Kirstein
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

7.  Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.

Authors:  Shoshana M Rosenberg; Michaela S Tracy; Meghan E Meyer; Karen Sepucha; Shari Gelber; Judi Hirshfield-Bartek; Susan Troyan; Monica Morrow; Lidia Schapira; Steven E Come; Eric P Winer; Ann H Partridge
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

8.  Contralateral prophylactic mastectomy in the American College of Radiology Imaging Network 6667 trial: effect of breast MR imaging assessments and patient characteristics.

Authors:  Habib Rahbar; Lucy G Hanna; Constantine Gatsonis; Mary C Mahoney; Mitchell D Schnall; Wendy B DeMartini; Constance D Lehman
Journal:  Radiology       Date:  2014-06-16       Impact factor: 11.105

9.  Considerations arising from requests from patients for a bilateral mastectomy who are eligible for breast-conserving surgery: Factors weighing for and against performing the operation.

Authors:  Alessandro Fancellu
Journal:  Oncol Lett       Date:  2016-05-30       Impact factor: 2.967

10.  Contralateral prophylactic mastectomy rate stable at major Canadian breast cancer center.

Authors:  Amanda Roberts; Lakhbir Sandhu; Tulin D Cil; Stefan O P Hofer; Toni Zhong
Journal:  World J Clin Oncol       Date:  2016-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.